Antonio M.
- Country
- Portugal
- Department
- Pneumologia
Research Overview
- A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Admilparant in Participants with Idiopathic Pulmonary Fibrosis
- A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Admilparant in Participants with Progressive Pulmonary Fibrosis
- Efficacy and Safety Evaluation of TAR-200 and Cetrelimab in High-Risk Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guérin
Data & Insights
Has run more than one trial at 92 of 155 partner sites.
Specializations
Pulmonary Medicine
The investigator specializes in studying advanced treatments for rare respiratory conditions, particularly focusing on autoimmune pulmonary alveolar proteinosis (aPAP). Their research explores innovative therapeutic approaches using inhaled nebulizer solutions for patients with respiratory disorders.
- Rare Lung Diseases
- Autoimmune Respiratory Conditions
- Inhalation Therapy
Their work encompasses the evaluation of novel therapeutic agents for chronic respiratory conditions, with particular attention to daily treatment regimens.
Urologic Oncology
The investigator conducts research in the field of bladder cancer treatment, with specific expertise in managing non-muscle-invasive bladder cancer (NMIBC). Their work includes investigating combination therapies for high-risk patients who have not responded to conventional treatments.
- Bladder Cancer Therapeutics
- Novel Treatment Combinations
- High-Risk Cancer Management
The research focuses on alternative therapeutic options for patients who are ineligible for or have elected not to undergo radical surgical interventions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.